Frank Sinatra sung about making it in a city that doesn’t sleep which apparently also doesn’t donate much sperm either. With declining revenues, Proteonomix Inc. (PROT) dumped its only source of income, The Sperm Bank of New York in April, 2012. It didn’t matter since the spunk had little to do with PROT stock price appreciation in January. Yet, with no operating income now, you would have to be as dumb as Octomom to not take a close look at this explosive biotech which is on the verge of changing the world.
Our New Alert Is Set For Mid-September! Click HERE To Make Sure You Don’t Miss It!
PROT Stock Chart
Market Cap: 18.11M
Close: 2.29, up 0.46 (25.14%)
Volume: 75,557
Dollar Volume: $153,357
High: 2.51
Trades: 69
Average Trade Size: 1,095
52 Week Range: 0.29 to 7.18
Authorized: 240,000,000
Issued and Outstanding: 7,910,556
Proteonomix shares could have been snatched up for as low as 0.37 on the first trading session of the year, January 3rd. PROT hit 7.18 on the 27th of January with volume of 662,591 for a maximum gain of 1,840.54%.
Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE
Note: On April 24, 2012, Proteonomix received a subpoena from the SEC for a number of documents and correspondence pursuant to a formal investigation. (see here) The Company has made internal changes to address the issues by hiring a new CPA firm as well as appointing seasoned professionals to act as CFO and Treasurer of the Company. (see here)
Although the starting point was a few cents off from how the bull rally began at the end of 2011, PROT stock gained 472.50% in August. The biotech has love, no doubt, and hardly any outstanding shares which only increases the chances for huge gains. Why so much love since December 27th you ask?
On December 27, 2011, Proteonomix made its required payment to begin a Clinical Study entitled “UMK-121 in Patients with Liver Disease.” The Company had, prior to this date, entered into an Agreement to conduct the clinical trial with the University of Miami which stipulated that the University pay expenses associated with the clinical study and that Proteonomix assist financially.
The clinical study is focused on UMK-121 pharmaceutical therapy’s advancement toward its first human clinical trial in End Stage Liver Disease patients. According to United Network for Organ Sharing, there are more than 100,000 patients on the transplant waiting list at any given time and more than 500,000 patients in end stage Kidney disease with a staggering 60,000 plus Americans who suffer from End Stage Liver Disease.
Two weeks ago, the FDA granted permission to Proteonomix to initiate a Phase 1 clinical trial with its mobilization technology UMK-121. The technology, UMK-121, is a patent-pending combination of two FDA-approved drugs designed to mobilize mesenchymal stem cells from the bone marrow to the peripheral circulation. The combination drug is designed to reduce inflammation and increase angiogenesis to restore liver function.
But that’s not all that Proteonomix is in the mix with. On May 24, 2010, The Company launched its retail web site, www.proteoderm.com, and started accepting pre-orders for its anti-aging line of skin care products which are set to begin selling in Q4, 2012. Proteoderm contains Matrix NC-138, an anti-aging bioactive ingredient, and is the first product in the Company’s pipeline that was a result of their stem cell and collagen growth R & D program.
Something to Consider About PROT Stock
Almost one year ago, Gilead Sciences (GILD) pulled no punches by taking the pole position in developing the next generation of hepatitis C drugs when they agreed to pay $11 billion in cash for Princeton N.J. based Pharmasset. The purchase to capture what, at the time, was the first all-oral treatment regimen, PSI-7977, which had entered the final phase of clinical testing.
If Proteonomix can come back with positive news that is indicative of longer survival rates with little to no side affects, or better yet, a cure to End Stage Liver Disease, PROT shareholders will laughing all the way to the bank.
Imagine if on December 27th, the exact same day North Springs Resources (NSRS) began their pump and dump orchestrated by Awesome Penny Stocks and their affiliates, you would have invested in PROT stock instead. You could have chosen between the 66,734 shares of PROT that traded between 0.30 and 0.38, or the 97,126,736 of NSRS that traded between 0.14 and 0.244. NSRS maxed out at $1.72 for a maximum gain of 1,128.57% while PROT maxed out at $7.18 for a maximum gain of 2,293.33%.
The point: With the Pristine Solutions (PRTN) pump underway, investing in PROT stock has already outperformed the pump and dumpers #2Flusher penny stock and won’t even come close to offering the gains Proteonomix shareholders have already achieved in August or beyond.
About PROT Stock
Proteonomix, Inc. is a biotechnology company engaged in the discovery and development of cell therapeutic products. The Company is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases as well as for bone marrow and organ transplants. The Company’s discoveries involve cell treatments.
The Company entered into the development stage as of April 1, 2012 while they further their research and development of their core technology. On April 30, 2012, the Company disposed of its lone operating subsidiary, The Sperm Bank of New York, Inc. Prior to April 30, 2012, the Company owned and operated seven subsidiaries, The Sperm Bank of New York, Inc., Proteoderm, Inc., National Stem Cell, Inc., PRTMI, StromaCel, Inc., XGen, LLC, and Thor Biopharma.
Bottom Line: If you like going long on penny stocks and love the chances of seeing huge gains on biotech stocks, get PROT on the list of penny stocks to buy.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
ShareSEP
